Comparing Nexien BioPharma (OTCMKTS:NXEN) and Ovid Therapeutics (NASDAQ:OVID)

Nexien BioPharma (OTCMKTS:NXENGet Free Report) and Ovid Therapeutics (NASDAQ:OVIDGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. 30.6% of Nexien BioPharma shares are owned by company insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nexien BioPharma and Ovid Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexien BioPharma 0 0 0 0 N/A
Ovid Therapeutics 0 2 4 0 2.67

Ovid Therapeutics has a consensus price target of $4.70, suggesting a potential upside of 571.33%. Given Ovid Therapeutics’ higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Nexien BioPharma.

Profitability

This table compares Nexien BioPharma and Ovid Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexien BioPharma N/A N/A -1,203.89%
Ovid Therapeutics -10,691.14% -53.62% -37.76%

Risk and Volatility

Nexien BioPharma has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nexien BioPharma and Ovid Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nexien BioPharma N/A N/A -$360,000.00 ($0.01) -1.69
Ovid Therapeutics $390,000.00 127.33 -$52.34 million ($0.73) -0.96

Nexien BioPharma has higher earnings, but lower revenue than Ovid Therapeutics. Nexien BioPharma is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Nexien BioPharma

(Get Free Report)

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

About Ovid Therapeutics

(Get Free Report)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Receive News & Ratings for Nexien BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexien BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.